Compare HLX & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HLX | IMCR |
|---|---|---|
| Founded | 1979 | 2008 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | 1996 | 2016 |
| Metric | HLX | IMCR |
|---|---|---|
| Price | $10.12 | $28.95 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 10 |
| Target Price | $11.50 | ★ $66.33 |
| AVG Volume (30 Days) | ★ 2.0M | 325.0K |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 30.39 |
| EPS | N/A | ★ 0.25 |
| Revenue | ★ $876,561,000.00 | $249,428,000.00 |
| Revenue This Year | $2.05 | $14.57 |
| Revenue Next Year | $5.46 | $8.21 |
| P/E Ratio | ★ N/A | $116.16 |
| Revenue Growth | 3.60 | ★ 43.05 |
| 52 Week Low | $5.52 | $27.56 |
| 52 Week High | $10.75 | $40.71 |
| Indicator | HLX | IMCR |
|---|---|---|
| Relative Strength Index (RSI) | 55.74 | 41.69 |
| Support Level | $9.22 | $27.56 |
| Resistance Level | $10.52 | $31.56 |
| Average True Range (ATR) | 0.33 | 1.25 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 60.56 | 25.48 |
Helix Energy Solutions Group Inc is an offshore energy services company. It provides specialty services to the offshore energy industry, with an emphasis on well intervention and robotics operations. Helix provides services in deep water in the Gulf of Mexico, Brazil, the North Sea, Asia Pacific and West Africa regions. It has four segments: Well Intervention, Robotics, Shallow Water Abandonment and Production Facilities. The Well Intervention segment includes vessels and equipment used to perform well intervention services in the Gulf of Mexico, the North Sea and Brazil. It derives the majority of its revenue from the U.S., and it also has its presence in North Sea, Brazil, Asia Pacific, West Africa, and Other.
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.